Mantle-cell lymphoma accounts for approximately 5 to 7% of all lymphomas, and in North America and Europe, the frequency is similar to that of noncutaneous, peripheral T-cell lymphomas. The median age ...

In equatorial Africa, a region of the globe known as the "lymphoma belt," children are ten times more likely than in other parts of the world to develop Burkitt's lymphoma, a highly aggressive blood ...

Low-grade lymphomas are a non-Hodgkin lymphoma (NHL) subtype. They typically grow more slowly and cause fewer symptoms than NHLs. They still require ongoing monitoring and treatment. There are two ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

The lymphatic system is the network of vessels, tissues, and organs that are part of the body’s immune system. Lymphoma develops in infection-fighting cells called lymphocytes that circulate through ...

Stage 2 Hodgkin’s lymphoma is an early stage of this cancer. Healthcare professionals describe Hodgkin’s lymphoma as stage 2 when a person has cancer in two or more lymph node groups, either below or ...

Recent news reveals Full House star Dave Coulier is battling stage 3 lymphoma, drawing attention and concern from fans worldwide. Many are eager to learn what led to his diagnosis, the treatments he’s ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

Being treated for Hodgkin lymphoma during childhood can result in fertility declines, a recent study shows. Pregnancy after cancer treatment can come with complications for a patient with Hodgkin ...

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...

Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...